Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)

Simply Wall St.05-15 13:48

In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635062227?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","is_english":true,"pubTime":"2026-05-15 13:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635062227","market":"us","top_or_hot":-1,"title":"Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)","media":"Simply Wall St.","content":"<div>\n<p>In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/exact-sciences-deal-and-legal-pressures-might-change-the-cas\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-15 13:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/exact-sciences-deal-and-legal-pressures-might-change-the-cas><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/exact-sciences-deal-and-legal-pressures-might-change-the-cas\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/exact-sciences-deal-and-legal-pressures-might-change-the-cas","article_id":"2635062227","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/exact-sciences-deal-and-legal-pressures-might-change-the-cas","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635062227","pubTimestamp":1778824090,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand in cancer diagnostics, and continued to contend with extensive infant formula-related litigation and a securities class action. \nAt the same time, the company’s decade-high dividend yield, long record of consecutive quarterly payouts, and growing medical devices footprint contrast with...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4082":"医疗保健设备","EXAS":"精密科学","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4592":"伊斯兰概念","BK4504":"桥水持仓","BK4585":"ETF&股票定投概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","ABT":"雅培","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4548":"巴美列捷福持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","ABT.AU":"Abundant Produce","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4581":"高盛持仓","SG9999002232.USD":"Allianz Global High Payout USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4588":"碎股","SG9999002224.SGD":"Allianz Global High Payout SGD","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC"},"translate_title":"Exact Sciences交易和法律压力可能会改变投资雅培(ABT)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT.AU":1.5,"ABT":1.5,"EXAS":1.5},"content_text":"In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand in cancer diagnostics, and continued to contend with extensive infant formula-related litigation and a securities class action.  At the same time, the company’s decade-high dividend yield, long record of consecutive quarterly payouts, and growing medical devices footprint contrast with heightened regulatory and legal pressures on its nutrition business.  We’ll now examine how the Exact Sciences acquisition, with its integration complexity and short‑term dilution, may reshape Abbott’s investment narrative. We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementAbbott Laboratories Investment Narrative RecapTo own Abbott today, I think you need to believe in its ability to compound value through medical devices and diagnostics while managing legal and regulatory overhangs in nutrition. The near term story now pivots on how smoothly Abbott integrates Exact Sciences, with short term EPS dilution and execution risk, while the most immediate threat remains extensive infant formula litigation and the related securities class action, which the latest news reinforces as a material legal and reputational issue. The completion of the roughly US$21.00 billion Exact Sciences acquisition feels like the clearest swing factor tied to the current news flow, because it expands Abbott’s cancer diagnostics reach just as the market is reassessing its execution and growth profile. Q1 2026 results modestly ahead of expectations suggest the core business is holding up, but the integration complexity, valuation reset, and ongoing legal pressures could shape how quickly any potential benefits from cancer diagnostics are reflected in sentiment. Yet behind Abbott’s long dividend record and cancer diagnostics expansion, investors should also be aware of the scope of its infant formula and securities litigation exposure... Read the full narrative on Abbott Laboratories (it's free!)Abbott Laboratories' narrative projects $59.7 billion revenue and $9.5 billion earnings by 2029. This implies 9.7% yearly revenue growth and an earnings increase of about $3.2 billion from $6.3 billion today.Uncover how Abbott Laboratories' forecasts yield a $118.64 fair value, a 40% upside to its current price.Exploring Other PerspectivesABT 1-Year Stock Price Chart Five members of the Simply Wall St Community currently see Abbott’s fair value between US$118.64 and about US$135.71, highlighting a fairly tight cluster of higher estimates. You may want to weigh those views against the legal and regulatory risks around infant formula and securities litigation that could influence how much of the devices and diagnostics potential actually reaches shareholders over time.Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 60% more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Abbott Laboratories research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.Searching For A Fresh Perspective?Every day counts. These free picks are already gaining attention. See them before the crowd does:Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Uncover the next big thing with 27 elite penny stocks that balance risk and reward.AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635062227","isCrawlerRequest":true}